Ocuphire Pharma
program evaluating for the reversal of mydriasis | Ocuphire Pharma
Company
Deck Type
Deck date
March 2022
Slide
28 of 38
Similar slides by Ocuphire Pharma
See diffirences between slides (animation)
Investor Day
January 2022
program evaluating for the reversal of mydriasis | Ocuphire Pharma
Related slides by other companies
Navidea Biopharmaceuticals
Investor Presentation
May 2022
path to submission | Navidea Biopharmaceuticals
Fusion Pharmaceuticals
Investor Presentation
January 2024
program milestones patients | Fusion Pharmaceuticals
NeuroSense Therapeutics
Investor Presentation
October 2024
focused pipeline go | NeuroSense Therapeutics
BioNTech
Results
November 2020
global development program expanded to additional regions regulatory submission on a rolling basis to and health canada initiated in act phase phase | BioNTech
Other recent decks by Ocuphire Pharma
See all presentations (10 decks)
Investor Presentation
November 2023
Investor Presentation
August 2023
Investor Presentation
May 2023
Results
January 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights